Why is argenx stock surging today?
argenx SE stock surged 4.0% today after the global immunology company announced it had entered into a definitive agreement to acquire Unnatural Products, Inc. (UNP), a California-based biotech specializing in orally-delivered macrocyclic peptides, for a total potential value of up to approximately $1.15 billion.
The deal includes $550 million payable upfront from cash on hand, with the remaining amount contingent on the achievement of development and regulatory milestones.
The strategic rationale centers on broadening argenx’s drug discovery toolkit: UNP’s macrocyclic peptide platform — built around AI-guided design, parallel synthesis, and direct-to-biology screening — pairs with argenx’s established antibody engineering to create new possibilities for oral and long-acting medicines targeting serious immune-mediated diseases.
CEO Karen Massey described the acquisition as adding capabilities "highly complementary to our antibody engineering" that create new possibilities for oral and long-acting medicines. UNP will retain its team and continue operating from its Santa Cruz, California site, which will serve as argenx’s peptide discovery hub, with closing expected by year-end.
The broader market backdrop provided little tailwind for the move: Belgium’s BEL 20 benchmark index edged slightly lower on the day, while U.S. markets were mixed, with the S&P 500 posting a modest gain and the Nasdaq trading in negative territory.
argenx’s sharp outperformance relative to both its domestic index and the broader healthcare sector underscores that today’s catalyst was firmly company-specific rather than macro-driven.
Taken together, the acquisition announcement gave investors a clear signal of argenx’s intent to invest disciplinarily in next-generation science, reinforcing confidence in its pipeline diversification strategy. With the stock trading at €848.2 — still meaningfully below its 52-week high of €925 — the market appears to view the deal as a credible step toward closing that gap.